MarginsXMarginsX
Home › Markets › Health Care › JBIO

Jade Biosciences Inc. (JBIO)

JBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$15.34
-4.99% on the day
Market cap
$975.3M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerJBIO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001798749
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
7.4 months
$80.4M cash at September 30, 2026
Share count, 1 year
+50.4%
2025-11-07 to 2026-11-06 · +8652.2% over 3 years
Going-concern doubt
No
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern."
10-Q 2026-11-13
Cash and burn$80.4M cash; operating cash flow -$32.6M a quarter.Report 2026-09-30
Shares outstanding69,189,448 (2026-11-06); 46,004,205 a year earlier; 27,668,887 three years earlier. 3y figure adjusted for split (1-for-35 overall).Cover page 2026-11-06
Reverse splits, 3 years1; latest 1-for-35 on 2025-04-29Source 2025-04-29
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-06-04
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months8-K 4.01 2025-05-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$35.1M-$28.9M$80.4MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q2 2026
2026-06-30
Not filed-$55.8M-$43.7M$107.3MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q1 2026
2026-03-31
Not filed-$40.4M-$24.1M$55.1MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q4 2025
2025-12-31
Not filed-$31.9M-$33.6M$88.4MNo debt tagsNeeds four quarters10-K 2026-03-06
Q3 2025
2025-09-30
Not filed-$25.2M-$22.1M$50.1MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q2 2025
2025-06-30
Not filed-$32.1M-$20.2M$220.9MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q1 2025
2025-03-31
Not filed-$38.2M-$18.8M$44.2MNo debt tagsNeeds four quarters10-Q 2026-11-13
Q4 2024
2024-12-31
Not filed-$5.4M-$11.0M$69.4MNo debt tagsNeeds four quarters10-K 2025-03-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-06-04
Latest annual report10-K2026-03-06
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-06-05

Source: SEC EDGAR submissions feed, 515 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+7.1%
1 month+20.3%
3 months-32.2%
Year to date+4.6%
1 year+66.7%
From 52-week high-39.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
VSTMVerastem Inc.$7.70-5.87%$970.3M
SVRASavara Inc.$4.46-3.77%$985.1M
MLTXMoonLake Immunotherapeutics$11.73-6.16%$998.3M
CYRXCryoPort Inc.$19.80-0.45%$1.0B
SPTXSeaport Therapeutics Inc.$19.12-4.30%$1.0B
MTRIMentari Therapeutics Inc.$19.87+6.83%$1.0B
AKTSAktis Oncology Inc.$16.16-2.77%$901.7M
CRVSCorvus Pharmaceuticals Inc.$10.60-0.38%$894.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier